Roche and PSS Sign Agreement to Develop a Fully Automated Workflow Solution for Next-generation Sequencing Platforms
PENZBERG, Germany and MATSUDO, Japan, December 21, 2012 /PRNewswire/ –
Roche and Precision System Science, Co., Ltd (PSS) today announced the signing of an
exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument
for Roche’s portfolio of next-generation sequencing platforms. It is intended to support
Roche’s GS Junior and GS FLX+ systems as well as the sequencing platforms that Roche is
Until now, upfront preparation of genomic samples has been a time-consuming and
complicated manual process within the sequencing workflow. The new instrument will be
designed to streamline the sample preparation workflow by automating the entire emulsion
PCR process thereby reducing the total hands-on time from several hours to a few minutes.
“This partnership aims to address one of the key needs of sequencing customers,” said
Dan Zabrowski, Head of Roche Applied Science. “The automated solution will not only
improve the efficiency of laboratory workflows, but also increase the reproducibility of
results by eliminating manual workload. This development program has made great progress
over the last year, and we are looking forward to working with PSS because they offer
outstanding expertise and have a strong track record in developing fully automated
“We are delighted that PSS and Roche are expanding their long-standing relationship in
automated DNA extraction to the challenging field of DNA sequencing,” said Hideji Tajima,
President of PSS. “Preparing samples for sequencing is a complex, high-skill process that
continues to hamper broader use of the technology. We believe that together PSS and Roche
will be able to develop an automated instrument that helps overcome this obstacle and
promote greater use of advanced sequencing systems.”
The agreement builds on a long-term reciprocal relationship between Roche and PSS. The
two companies first started to collaborate on automated DNA extraction fifteen years ago,
a partnership that resulted in the successful development and marketing of nucleic acid
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare
with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare
strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned
member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For
more information: http://www.roche.com.
About Precision Science Systems, Co., Ltd (PSS)
PSS, located at Matsudo, Japan, is a leading global provider of laboratory instruments
for nucleic acid extraction. The company specializes in the development and production of
automated instruments. As an original equipment manufacturer, PSS is also a leader in
developing and manufacturing OEM instruments and components that are then distributed by
partner companies. Founded as a maintenance and service company for clinical laboratory
instruments in 1985, the company has manufacturing, research and development sites in
Japan and maintains sales and service networks in the US and Europe. Registered shares of
PSS are traded on the JASDAQ under ticker code 7707.
For more information, please visit http://www.pss.co.jp.
For life science research only. Not for use in diagnostic procedures.
EMPCR, GS JUNIOR and GS FLX are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact: Roche Diagnostics Dr Claudia Schmitt Phone: +49-885-6601-0210 Email: firstname.lastname@example.org
SOURCE Roche Diagnostics GmbH